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ABSTRACT 
 
 
Respiratory Syncytial Virus (RSV) is a potentially life-threatening respiratory 
pathogen that infects approximately 64 million children and immunocompromised adults 
globally per year. Currently, there is a need for prophylactic and therapeutic approaches 
effective against primary and secondary RSV infections. This project focuses on the 
development of a simple, smart, and scalable anti-RSV nanotherapeutic that combines 
novel cellular antiviral defense mechanisms targeting the inhibition of viral fusion and 
replication. An ICAM-1 targeted liposomal nanocarrier will be synthesized and coated 
with a layer of chitosan containing the anti-fusion HR2-D peptide as an extracellular 
defense mechanism. Additionally, chitosan complexed to dual expressing short hairpin 
RNA (shRNA) recombinant plasmids will be encapsulated within the nanocarrier, and 
provide an intracellular defense mechanism that will interfere with the expression of the 
NS1 and P proteins. In combination, both defense mechanisms were expected to 
induce a synergistic anti-RSV effect that will surpass those of conventional therapeutics. 
Through this research, the NS1 and P containing plasmid (pSH-NS1-P) was cloned, 
and the nanotherapeutic was successfully synthesized. Based on the acquired results, 
pSH-NS1-P was shown to express anti-RSV effects, and it was also concluded that 
both inserts were producing active shRNA’s. Additionally, the anti-RSV efficiency of 
HR2-D was confirmed. Overall, this research exemplifies the anti-RSV efficiency of both 
defense mechanism, and also the successful synthesis of the proposed nano-scale 
delivery vehicle. 
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CHAPTER 1:  
INTRODUCTION 
 
Respiratory Syncytial Virus 
Respiratory Syncytial Virus (RSV) is a species of respiratory pathogen belonging 
to the taxonomical Family Paramyxoviridae of the Genus Pneumovirus [1][2]. RSV 
infections are the leading cause of bronchiolitis and pneumonia in infants, and severe 
lower respiratory tract infections in immuodeficient adults and the elderly [3]. These 
populations of induvial are at higher risk due to the lack of adequate host factors that 
can defend against RSVs antagonism against the host’s immune system [1].  On a 
global scale, there are 64 million cases of RSV reported per year, and 200,000 of those 
cases result in death [3]. It has been found that nearly 90% of infants under the age of 
two become infected with RSV, and in the US 400 infants die per year [1][5]. 
Additionally, infants fail to develop complete immunity, which makes them vulnerable to 
RSV infections later in life [4][5]. Additionally, RSV’s antagonism on the immune system 
is exacerbated in elderly whom already have compromised immune systems, and every 
year in the US 10,000 people over the age of 64 years old die [3]. However, RSV is a 
heterogeneous virus in regards to the pathogenesis exemplified between various strains 
and mutational variants. As a result, RSV has been linked to a wide range of lower and 
upper respiratory tract infections that cause mild symptoms in some individuals, while 
others are put at risk of mortality. 
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RSV: Virion and Genome 
RSV is an enveloped virus that contains a non-segmented, negative-sense 
single-stranded RNA genome, 15 kbp [1-3]. The genome encodes ten coding mRNAs 
that translate into eleven mature proteins after post-translational processing. These viral 
proteins have either a structural or non-structural role in the reproduction, infectivity, and 
propagation of RSV [1-3]. RSV’s envelope is derived from the cell membrane of infected 
cells during a process called budding, which results in spherical virions ranging from 
150-300 nm [3].  
Three RSV-encoded structural transmembrane proteins are incorporated into the 
envelope to form protruding motifs that facilitate cellular attachment, fusion, and entry 
[1]. The large glycoprotein (G) and the fusion (F) protein both facilitate cellular 
attachment through cell surface receptor recognition [6]. The G protein also aids in the 
evasion of recognition by the host cells immune system due to the presence of a motif 
that has a biomimetic structure to the chemokine, fractalkine [1][7]. This motif decreases 
the influx of immune cells to the site of infection within the lungs [1][7]. However, the F 
protein has been shown to be vital for RSVs fusion to the host cell’s membrane so that 
the viral genome can be inserted into the cytoplasm [1][8]. F is also the driving force 
behind the formation of syncytium in infected cells, which is the cytopathic fusion of 
neighboring cells that occurs due to the presence of F on the surface of infected cells 
[3][8]. The third envelope protein is the small hydrophobic (SH) protein, which is 
classified as a virioporin protein due to its production of ion channel-like pentameric 
pore-like structures that present activity specific to cations [1][10]. This activity results in 
the modification of the host cell membranes permeability, and reduces apoptosis in 
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infected cells. The result of this is a prolonged period of time for RSV to replicate and 
propagate [10]. 
Along the inner face of the envelope the non-glycosylated matrix (M) protein 
forms the inner-matrix space between the envelope and the nucleocapsid [1][11]. M 
plays a role in the morphogenesis of new RSV virions [11]. Additionally, M has been 
found to translocate into the cell’s nucleus in the early phases of infection where it 
inhibits the host cells transcription [3]. Later in the infection cycle the cytoplasmic levels 
of M increase and it begins to associate with viral inclusion bodies, which are protein 
complexes that facilitate viral RNA synthesis [1][11]. In the cytoplasm, M indirectly 
silences RSV RNA synthesis by facilitating the formation of the nucleocapsid 
complexes, which are then delivered to the inner-wall of the plasma membrane for 
budding [1].  
The nucleocapsid consists of four viral proteins (N, P, L, M2-1), that all work 
together to protect and transcribe the genome [1][3]. The nucleoprotein, N, protein binds 
the entire length of the RNA genome or antigenome to form stable helical 
nucleocapsids, which act as the templates for RNA synthesis or are encapsulated in 
new RSV virions during budding [12]. The N protein forms a flexible connection that 
allows the RdRP to gain access to the template [1]. The N protein was also found to 
prevent the phosphorylation of eIF-2a through its interactions with the double-stranded 
RNA protein kinase, which antagonizes the host immunity through inhibition of protein 
synthesis [1][12].  In cohort with the phosphoprotein, P, the RNA genome is 
encapsidated, which prevents host cell recognition and subsequent degradation or 
initiation of innate immune responses [1][2]. P binds and delivers free N proteins to 
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naked genomes or antigenomes, and also positions the L protein on the nucleocapsid 
[5]. However, P’s primary function is that of a subunit of the RNA-dependent RNA 
polymerase, RDRP. The P subunit is vital for the formation of the active RdRP 
holoenzyme by presenting binding sites that facilitate the attachment of the N, M2-1, 
and the L proteins [1][2]. P ‘s function in the RdRP also initiates the necessary 
conformational changes that grant it access to the RNA templates, and facilitates 
clearance of the promoter site and chain elongation. P is phosphorylated at 10-12 sites, 
which creates different turnover rates due to the interaction with cellular kinases and 
phosphatases that degrade P’s functionality [1].  
The L protein is the large subunit of the RdRP, which recognizes the 3’ promoter 
site of the genome. The L protein also contains a polymerization domain that is involved 
in the capping of nucleotides [1][2]. The M2-1 protein is the transcription processivity 
factor, and has been found to bind to RSV mRNAs, and also interact with the P protein 
for its incorporation into viral inclusion bodies [13]. M2-1 also transports M proteins to 
the inclusion bodies [13]. M2-1 contains a zinc-finger motif that is involved in the 
destabilization of host response mRNAs such as for cytokines [13] 
The M2-2 protein functions completely as a regulatory protein that controls RSVs 
propagation by regulating the transcription and RNA replication. As RNA synthesis 
occurs in an infected cell the M2-2 levels increase, which has been linked to the down 
regulation of RSV RNA synthesis [1]. However, initially during infection the levels are 
low and RNA synthesis continues as normal. Additionally, there are two non-structural 
proteins, NS1 and NS2, that work individually and synergistically to antagonize the 
induction and signaling of type I interferons (IFNs), and also inhibit apoptosis in infected 
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cells to facilitates prolonged propagation [1-5][14][17]. NS1 knockdown inhibits RSV 
replication and infection by upregulating cellular IFN and apoptosis due to the 
consequential knockdown of mitochondrial antiviral signaling (MAVS) [27][29][32]. 
 
RSV: Infection Lifecycle 
Initially, a living organism gets infected with RSV due to the direct contact with 
objects containing RSV on its surface or with an infected persons sneeze or cough. 
Once an individual is infected, RSV virions translocate to the lungs where it may travel 
and infect the alveoli region. RSV binds and fuses with lung cells via the G and F 
proteins. The F protein also stimulates the fusion of the RSV envelope with the cell 
membrane, which allows RSV to cytoplasmically insert its RNA genome in the form of 
nucleocapsids. RSV and its replication components, viral proteins and mRNA, have 
been detected within cells four to six hours post infection [3]. The genome is able to 
replicate and be transcribed independent of the nucleus due to the encoding of the 
required proteins to form the complete holoenzyme of the RNA-dependent RNA 
Polymerase (RdRP). Initially the genome is replicated with host polymerases, but after 
the first round of transcription and translation the RDRP is formed and carries out the 
remainder of the events. The negative sense genome is replicate into positive-sense 
antigenomes and negative-sense genomes. The antigenomes are transcribes to form 
new negative-sense genomes for their utilization as the template for translation or for 
their incorporation into new RSV particles. 
Maximum levels of intracellular RSV proteins and mRNA is reached at around 
15-20 hours [3]. This is also about the time that the M2-2 protein downregulates 
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transcription in order to promote the replication of the genome for its integration into 
new virions [3]. The new genomes are bound with the N protein to form stable 
nucleocapsids that are brought to the inner face of the plasma membrane by the M 
protein. Then a process called budding occurs where the nucleocapsid and is 
encapsulated, along with other RSV proteins, within a spherical lipid-based envelope. 
During this process apical recycling endosomes are utilized by RSV for the 
encapsulation of the nucleocapsid, but this also allows RSV to exit the cell through a 
natural pathway. This release of new RSV virions has been found to initiate around 
twelve hours post infection, and reach its max release at 24h. This release remains at 
this peak release until the cell dies due to the infection, which typically occurs after the 
cell has been infected for 30-48h [3]. 
 The infected cells morphologies are altered due to the presence of the viral 
proteins. In many cases, the viral glycoproteins insert themselves into the plasma 
membrane and form filamentous surface projections that facilitate the development of 
syncytium [1]. Recently it has been identified that RSV infections can manifest in 
extrapulmonary immune cells such as in blood and bone marrow [5][31]. This occurs 
when the infection damages the epithelial cell wall of the lung thus allowing RSV to 
spread to various immune-privileged sites that confer a safer environment for RSV 
replication [5][28]. 
 
Current Therapeutic Approaches 
Based upon the increasing knowledge regarding RSV’s infection lifecycle and 
immune evasion mechanisms researchers have begun working towards the 
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development of effective, safe, and affordable anti-RSV therapeutics that can 
outperform the currently available, low-efficacy, therapies [1-3]. There is a high demand 
for this research due to the lack of safe vaccines or affordable prophylactics for the 
widespread pre-emptive therapy of “at-risk” populations. Scientists have attempted to 
formulate vaccines for RSV, but they have all been proven to be ineffective or harmful to 
the patient. In the 1960’s, formalin-inactivated RSV was utilized as a vaccine, but ended 
up causing mortality in some of the treated infants [5]. The current research is being 
focused on the development of attenuated-live and subunit-based anti-RSV vaccines 
[5][15]. However, RSV presents a challenging infection lifecycle that makes it hard to 
develop effective anti-RSV therapeutics [9][15]. Additionally, RSV is a very 
heterogeneous virus in regards to the homology between strains, which makes it difficult 
to develop therapeutics to work against all variants [9]. In response, researchers have 
been developing therapeutics that targets the most conserved viral molecular sites [26]. 
 Currently, the only available and utilized anti-RSV therapeutic is called Ribavirin, 
but lacks long-term efficacy [3]. However, two passive immunoprophylactic antibody 
therapies have been produced that are utilized to treat individuals of “at-risk” 
populations [5]. The two therapeutics are Synagis, a polyclonal RSV antibody, and 
Palivizumab, a monoclonal anti-F antibody. Due to the higher specificity of Palivizumab 
it has been used in infants since the 1990s to confer passive immunity for up to a month 
per injection [5]. The problem is that the RSV season is 5-months, which means the 
infant must receive at least five health-care administered injection. Additionally, the 
injection is expensive, and also presents the risk of producing RSV resistant strains [3]. 
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Therefore, the goal of novel anti-RSV therapeutics is focused on creating an affordable, 
high-efficacy, and long-lasting prophylactic therapies. 
 
Novel Therapeutic Approaches 
Recently, with the rise of biomedical nanotechnology, the uses of nanoparticles  
(NPs) have been applied for the significant enhancement of the delivery of anti-RSV 
therapeutics. In regards to RSV, the small size of NPs allows them to translocate into 
the alveoli region of the lungs for the treatment of lower respiratory tract infections. 
 Nanotherapeutics offer a wide-range of benefits that significantly enhance the 
drug delivery and release profiles for therapeutics. Liposomes are lipid-based 
nanocarriers that contain an inner compartment that can be loaded with therapeutic 
payloads. Liposomes also facilitate a high level of functionalization, which allows them 
to be designed to display unique activity through the addition of targeting, stabilizing, 
and stimuli-responsive components. Liposomes synthesis is highly dependent on the 
self-assembly of biocompatible lipid molecules. [16] 
 Another nanoparticle that has recently been incorporated is Chitosan, which is a 
cationic polysaccharide derived from the exoskeletons of crustaceans, but has been 
recently exploited for the delivery of genes and drugs based upon its biocompatible 
properties, low immunogenicity, and lack of toxicity [3]. In addition, chitosan’s positive 
charge makes it a stable delivery vehicle for nucleic acids due to the strong electrostatic 
interaction with the negative backbone of DNA. Chitosan has also been found to 
present immunostimulatory properties that have been exploited for the enhancement of 
vaccine efficacy. However, in regards to chitosan’s utilization towards the treatment of 
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RSV is greatly benefited by the mucoadhesive properties that enhances the trans- or 
para- cellular transport of mucosal epithelial walls. These properties allow chitosan-
based therapeutics to modulate the immunity of lymphoid tissues, including those within 
the lungs [3]. 
 
 RNA Interference via shRNA 
RNA interference (RNAi) is a process that occurs within the cytoplasm of target 
cells, and presents an activity that inhibits or downregulates the expression of specific 
genes by targeting the corresponding mRNA sequence [18-22]. RNAi’s activity is driven 
from the production of small double stranded RNA sequences that range from 19 to 24 
nucleotides in length [18-19].  These RNA sequences are often produced within the cell, 
and are typically encoded via recombinant expression DNA plasmids [20].  The major 
focus of this therapeutic intervention is for the inhibition or antagonism towards the 
pathogensis or infectivity of a disease or virus. By targeting the protein-encoding 
sequences, they are not able to be translated into mature and complete proteins. The 
binding of the short interfering RNA recruits endogenous RNAse III enzyme that cleave 
the bound mRNA, rendering it inactive [18-22] 
 In particular, short hairpin RNAs (shRNAs) were used for this experimentation as 
the active agents for RNAi. shRNAs are inserted into an mammalian expression vector 
in the form of a palindromic sequence that is placed in the center of a dsDNA insert, 
which is ligated into the plasmid.  Once the plasmid enters a cell, it translocates to the 
nucleus and the host’s replication machinery is utilized to transcribe a single stranded 
RNA, which is then transported to the cytoplasm for RNAse III processing [21-23]. This 
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RNA then folds over itself due to the complementary nature of the palindromic 
sequence, which results in a dsRNA sequence that contains a loop sequence, hairpin, 
at one of the ends [21-23]. This hairpin structure specifically recruits the DICER 
enzyme, which cleaves the sequence at the loop and just upstream of the shRNA 
sequence. As a result, a final19-24bp dsRNA sequence is produced, and incorporated 
within the RNA Induced Silencing Complex (RISC) [18-22]. RISC then recognizes the 
target RNA sequence based upon the complementation of the shRNA sequence. RISC 
contains the enzyme Argonaute-2, which is then responsible for the cleavage of the 
complementary mRNA sequence upon binding [18-23]. In this experiment, the 
combination of shRNA’s targeting the NS1 and P gene are expected to create a 
synergistic anti-RSV effect due to the inhibition of IFN antagonism and formation of the 
RdRP [24][25]. 
 
 Novel Double Stapled Anti-F Peptide, HR2-D 
Currently, novel anti-F biomolecules, antibodies and peptides, are being 
developed and are offering highly effective modulatory anti-RSV therapies. In regards to 
RSV, a novel peptide called HR2-D competitively inhibits fusion by binding in the 
position of one of the heptad repeat (HR) domains of the RSV fusion (RSV-F) protein. 
The binding of HR2-D to the fusion protein inhibits the cellular internalization of RSV, 
thus preventing infection [30]. This binding renders the F protein inactive, and blocks its 
ability to attach and fuse with cell membranes, which results in the absence of infection 
by bound RSV virions. Therefore, HR2-D prevents the RSV infection extracellularly [30]. 
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 ICAM-I Targeting 
Recently it has been identified that ICAM-1 expression is upregulated on the 
surface of RSV infected cells [3]. Therefore, the incorporation of anti-ICAM-1 can direct 
therapeutics directly to infected cells, and facilitate its binding and endosomal 
internalization. It was also suggested that the F protein of RSV binds to ICAM-1 due to 
the induced inhibition of RSV infection when anti-ICAM-1 therapies have been utilized. 
 
Concept for Novel Anti-RSV Nanotherapeutic 
Based upon the information discussed in this introduction the following 
therapeutic approach has been designed. The route of administration that has been 
chosen is intranasal delivery due to its presentation of the most direct route to the lungs. 
The anti-RSV nanotherapeutic will be of the nanoscale, which will allow it to penetrate 
into the alveoli region of the lungs. A Liposome (DPPC:Chol) will be used as the 
nanocarrier, and on its surface a coating of chitosan will be applied that will contain the 
antibody anti-ICAM1 for the targeting of RSV infected cells. This chitosan layer will also 
contain the antibody HR2-D as the first mechanism of defense against RSV infection by 
inhibiting cell fusion extracellularly. However, in order to enhance the efficacy of this 
therapy, a second mechanism of defense has been added that will act intracellularly 
inhibit the propagation of RSV. Within the liposomes inner compartment chitosan 
nanoparticles (NP) complexed with dual-expressing shRNA plasmid DNA will be 
encapsulated. Upon ICAM1 binding, the nanotherapeutic will become internalized and 
the plasmid DNA will be cytoplasmically released. The plasmid will be transcribed by the 
host cell’s machinery, and will encode shRNA targeting the NS1 and P protein. The 
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shNS1 is expected to inhibit the antognizing effects of the NS1 protein thus allowing the 
host to induce an immune response against RSV. The shP is expected to inhibit the 
formation of the RdRP, which would eliminate RSV’s ability to replicate due to the lack 
of viral proteins. Overall, the final formulation of this nanotherapeutic is expected to be 
applicable for the prophylactic treatment of at-risk populations, and present a more 
affordable option. 
 
Hypothesis and Specific Aims 
The described nanotherapeutic is expected to inhibit the fusion of the RSV virion 
to lung cells through the inhibition induced by HR2-D, but if RSV ends up infecting cells 
then the recombinant shRNA-expressing plasmid will target the NS1 and P protein to 
inhibit the antagonizing effects on the IFN system and prevent replication by blocking 
the formation of the RDRP holoenzyme. The first aim of this project is to clone the 
recombinant plasmid, and the second aim is to synthesize the complete formulation. 
 
 
Figure 1. Administrative Route and Defense Mechanisms of the Anti-RSV Nanotherapeutic.  
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CHAPTER 2: 
MATERIAL AND METHODS 
 
Cloning of Recombinant Multi-shRNA Plasmid (pSH-NS1-P) 
The pSH plasmid used for the cloning of the pSH-
NS1-P plasmid was ordered through addgene.com 
(#12391), and delivered as transformed E.coli cells 
inoculated in an agar stab. pSH is a mammalian 
expression vector that contains three sites for the 
insertion of DNA inserts via restriction digestion and 
subsequent ligation. pSH utilizes the Human Ubiquitin C 
promoter (UbC) for the transcription of a single mRNA 
transcript that is post-modified to express a maximum of 
three short hairpin RNA’s (shRNA’s). The selectable 
markers present in pSH include enhanced green fluorescence protein (EGFP) for 
fluorescent detection, and ampicillin resistance as a selectable growth factor. 
 
 Isolation of Multi-shRNA Vector (pSH) 
The pSH/E.coli cells were aseptically quadrant streaked on Lauria Broth (LB) 
agar plates (37g Lb/L) containing Ampicillin (100μg/mL). A control plate was prepared 
with Kanamycin (50μg/mL). The inoculated plates were incubated overnight at 37⁰C. 
Figure 2. Multi-shRNA Plasmid Map 
14 
 
The next day individual colonies were transferred, using sterile toothpicks, into 500mL 
of liquid LB media (25g/L) containing Ampicillin (100μg/mL), and incubated in a shaker 
overnight at 37⁰C and 100rpm. After incubation, 1.5mL 50% glycerol stocks were 
prepared and stored at -80⁰C. pSH was isolated from the remaining liquid culture using 
Invitrogen’s Hi-Pure Maxi-Prep Kit [Catalog # K210006]. The concentration of the 
isolated plasmid was quantified using a ThermoScientific Nanodrop2000. Subsequent 
plasmid isolations were completed using the 50% glycerol stocks by inoculating 500mL 
of liquid LB media with 1.5mL of the stock. Then the protocol is repeated as discussed 
above.  
 Additionally, lyophilized stocks of an RFP expressing plasmid, pTomato (pTom), 
were re-suspended in TE buffer, and then transformed into DH5α E.coli cells via the 
heat shock method. 2.5μl of the pTom solution was added to 50μl of DH5α E.coli cells, 
and then the mixture was placed on ice for 25mins. The mixture was then placed in a 
42⁰C water bath for 45secs, and then placed back on ice. After 5mins 950μl of liquid LB 
was added to the mixture, and then inoculated on LB agar plates supplemented with 
Kanamycin (50μg/ml) for selection of pTom-transformed cells, and on a plate 
supplemented with Ampicillin (100μg/ml) as the control. Then, individual colonies were 
inoculated and pTom was isolated using the complete protocol as discussed for pSH.  
Confirmation of pSH nucleotide sequence. Three restriction digests were 
performed (protocol; section 2.1.3.) on pSH that used different combinations of 
restriction enzymes (Fig. 4). The digested fragments were analyzed via Agarose Gel 
Electrophoresis (AGE). 1% agarose gels were prepared using 1g Agarose in 100mL 1X 
TAE. The agarose was dissolved using heat, and then Ethidium Bromide (10 μg/mL) 
15 
 
was added to the molten solution. The solution was then poured into a gel mold with a 
10 well comb, and left at room temperature. The solidified gel was placed in the 
electrophoresis apparatus and submerged in running buffer, 1x Tris-Acetate-EDTA 
(TAE). Each sample was prepared for loading in a final volume of 24μl: 20μl of DNA 
(typically 1ug) diluted in nuclease-free water (nfH20), and 4μl of the 6x loading dye. A 
15kbp DNA Ladder was utilized as the reference for band size, and in every gel one 
well was loaded with 5μl of the ladder. The loaded gels were exposed to a 70Hz 
electrical current for 1 hr that runs negative to positive, and begins negatively at the 
wells. The gel was analyzed using UV-VIS spectroscopy to visualize the resulting 
bands. (This protocol was utilized for all AGE analysis) 
 
 Bioinformatic Analysis 
 The complete sequence for RSV’s genome and transcribed mRNA sequence 
was retrieved from the NCBI online database. The sequences utilized for the shRNA 
expressing double stranded DNA (dsDNA) inserts was designed based upon the results 
of the in-silico analysis of the NS1 and P gene sequences via siRNA Wizard 3.1 (Invivo 
Gen). The shRNA sequences (19-24bps) produced by the software generated 10 
sequences per gene, and gave each a score based upon their stability and expected 
efficiency. The three highest scored sequences were selected, and then were manually 
analyzed to ensure they met the standard guidelines. The selected shRNA sequences 
were analyzed using NCBI’s BLAST software to ensure that they expressed homology 
specifically to RSV genes, and not with any genes within the human genome, or other 
living organisms. Additionally, a BLAST analysis was completed to ensure that the 
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selected sequence expressed homology to all the common RSV strains. Once the 19-
24nt sequences were selected they were incorporated into the design of the dsDNA 
inserts as a palindrome, separated by a spacer, in the center of two flanking filler DNA 
sequences. The final inserts ranged from 109-114bps, and were ordered and 
synthesized by the company, Integrated DNA Technologies (IDT). 
 
 Cloning of pSH-NS1-P 
 Experimental design. The first digestion reaction was prepared using KpnI and 
EcoRI, which resulted in a linearized pSH with exposed restriction sites complementary 
to the 5’ and 3’ ends of the NS1 dsDNA insert for the subsequent ligation. The second 
digestion was performed on the ligated pSH-NS1 circular plasmid. PstI was used to 
linearize pSH-NS1, and provide complementary ligation sites for the P dsNDA insert. 
 Restriction digest. Digestion reactions were prepared as follows: 1μg pDNA, 5μl 
10X CutSmart Buffer, 1μl of each restriction enzyme used, 1μl CIP, and 40-43μl nfH20 
so the total volume is 50μl. The reaction was incubated at 37⁰C for 15 mins. A portion of 
the digestion reaction was analyzed using AGE. The EDTA in the loading buffer used 
for AGE inactivates the restriction enzymes, but the remaining amount of the reaction 
requires heat inactivation. The remainder was placed in a 65⁰C water-bath for 20 mins, 
and then stored at -20⁰C.  
  Ligation. Ligation reactions of 20μl were prepared as follows: 100 ng of digested 
pDNA (5μl), 300 ng of the NS1 insert DNA (1μl), 1μl Ligase, 10μl 2X Ligase Buffer, and 
3μl of nfH2O. The solution was mixed by pipetting up and down. Then incubated at 
room temperature for 5 mins, and stored at -20⁰C. 
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Transformation via heat shock method. The ligated plasmids were 
transformed into DH5α cells as described: 5μl of the ligation reaction was added to 50μl 
of DH5α cells, and then placed on ice for 30 mins. The reaction tube was then placed in 
a water-bath at 42⁰C for 30 secs. Then 950μl of LB media was added to the reaction 
tube. The 1ml reaction was then placed at 37⁰C on a shaker for 1 hr. After 1hr, LB agar 
plates were inoculated with the transformed cells, and incubated overnight at 37⁰C. The 
next day individual colonies were transferred into LB media with Ampicillin (100 μg/mL), 
and cultured in the same manner as previously discussed. 50mL were prepared for 
plasmid isolations between digestions using the Monarch Miniprep kit (New England 
Biolabs). For the final isolation of pSH-NS1-P 500mL was for a plasmid isolation using 
the HiPure Maxiprep kit (Invitrogen). Glycerol stocks were prepared for each plasmid. 
PCR of pSH-NS1-P. PCR reactions were prepared as follows: 1ng of pDNA, 
1.25 U TAQ Polymerase, 5μl of 10X buffer (NH4), 0.5μM of forward primer and  0.5μM 
of reverse primer, 1.5mM MgCl2, 5μl of dNTP mixture (0.2μM of each nucleotide), and 
nfH2O to make a total volume of 50μl. The PCR cycles were set for 2 mins at 95⁰C, and 
then 35 cycles of 30 secs at 95⁰C, 30 secs at 51.4⁰C, and 45 secs at 70⁰C. After all 
cycles are completed the samples were subjected to 5 mins at 70⁰C to complete the 
run. The resulting PCR products were analyzed using a 2% agarose gel via AGE. 
Sanger sequencing. The final plasmid, pSH-NS1-P, was isolated from a new 
liquid LB culture using New England Biolab’s Monarch Miniprep Plasmid Isolation kit 
(Catalog #T10105), but was eluted in nfH20, instead of TE buffer, because the EDTA 
interferes with the sequencing enzymes efficiency. The sample for sequencing was 
prepared using the cloned plasmid and a forward primer that bound within the first few 
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nucleotides of the NS1 sequence. The 10μl samples were placed in PCR strip-tubes, 
and then sent to Genewiz (company) for Sanger sequencing. Results were provided in 
an online format. 
 
Synthesis of Anti-RSV Nanoparticle 
The final Anti-RSV NP will be comprised of three layers that are each 
synthesized individually and sequentially, as seen in figure #. After the completion of 
each step, the resulting NPs will be characterized according to their size, zeta potential, 
and physical apperacne when visualize using Transmission Electron Microscopy (TEM). 
The first step is the synthesis of chitosan NPs complexed with plasmid DNA (CP). The 
second step is the encapsulation of the CP NPs within Liposomes composed of DPPC 
and cholesterol (2:1 lipid ratio, respectively). The final step is the coating of the CP- 
liposomes with a chitosan layer containing the HR2-D and the ant-ICAM1 antibody.  
 
Figure 3. Steps for the synthesis of the final dual-inhibiting anti-RSV nanotherapeutic 
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Synthesis of Chitosan-pDNA Core 
  First, a 1% Chitosan stock (10mg/mL) was prepared using 100mg of Chitosan in 
10ml of 1% acetic acid (10μl/mL). A magnetic stirring rod was added, and then it was 
placed on a stir plate until the Chitosan was homogenously dissolved. A 0.25% 
Chitosan solution (2.5mg/ml) was then prepared by adding 250μl of the 1% Chitosan 
stock to 750μl of 1% acetic acid. A final dilution was then prepared to make a 0.01% 
Chitosan solution (0.1mg/mL) by adding 400μl of the 0.25% Chitosan solution to 10mL 
of 5mM Sodium Acetate (68μg/mL). The pH of the 0.01% Chitosan solution was 
adjusted to a pH of 5.5 using 2M Sodium Hydroxide (80mg/mL). Second, a pDNA 
solution was prepared by adding 200μg of pDNA into a total volume of 9mL of 0.2μm 
filtered diH20. Then 1mL of 250mM Sodium Sulfate (35.5 μg/mL) was added to the 9mL 
pDNA solution. Both solutions, 0.01% Chitosan and pDNA, were then heated for 5 mins 
at 55⁰C using a water-bath. Both solutions were then vortexed for 1 min, and while 
vortexing the 0.01% Chitosan solution, the pDNA solution was added. The mixture was 
vortexed for a minute. A final centrifugation step was performed at 16k G for 1 min to 
separate aggregate and large particles, if present. The final solution contained CP NPs, 
and their size and zeta potential was analyzed using Malvern’s Zetasizer. Samples were 
prepared using the Malvern cuvettes and then placed in the instrument for analysis. 
 
  Synthesis of Liposome Nanocarrier 
  Liposomes were prepared using the Thin-Layer Hydrolysis method. A 2:1 ratio of 
DPPC (50mg) to Cholesterol (12.23mg) was used. Both lipids were dissolved in 10mL 
of 100% Chloroform. The lipid solution was transferred into a round-bottomed flask that 
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was then attached to a rotor evaporator. The flask was spun at 100rpm for 1hr with the 
water-bath at 60⁰C. After all the Chloroform evaporated, the flask was removed from the 
rotor evaporator, and 2.5mL of 1X PBS was added. The flask was subjected to a 60⁰C 
water-bath and a sonicator in order to completely dissolve the thin-lipid film. The 2.5mL 
solution was then transferred to a 15mL falcon tube. The solution was then sonicated 
using a probe sonicator for 30mins to reduce the final liposome size. Then the solution 
was centrifuged at 16k G for 10min to remove large particles and titanium particles 
produced from the probe. The supernatant was then transferred into a new 15mL falcon 
tube that was placed in a 70⁰C water bath for 30 mins for the annealing step. In order to 
coat the synthesized liposome with chitosan, a diluted sample of 1μg of chitosan was 
added to the liposome sample. The liposome solution was placed on a magnetic stirrer 
plate, and the chitosan solution was added dropwise at room temperature. The resulting 
liposomes and coated-liposomes were analyzed for their size using the Malverns 
Zetasizer as previously discussed. 
 
Cell Cultures: A549 and HEP-2 
A549 and human epithelial type 2 (HEp-2) cells were separately cultured in T75 
Filtered Flasks using Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 
10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (P/S). Inoculated flasks 
were incubated at 37⁰C in a humidified incubator with 5% CO2/95%. Cell cultures were 
passaged when the confluency reached 80-100%. The cells were detached from the 
flask using 3mL of Trypsin. The detached cells were removed from the flask and mixed 
with 7mL of DMEM in a 15mL falcon tube. The cells were then pelleted using 
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centrifugation for 4 mins at 1,500rpm. The supernatant was then removed, and the cell 
pellet was re-suspended in 10mL of supplemented DMEM. 10μl of the re-suspended 
cells was then used to determine the concentration of the cells per mL using the New-
Bauer Technique. Based on the upcoming experiment, in addition to a new flask, 6-, 24-
, or 96- well plates were seeded so that the initial confluency was 50-60%. Cell stocks 
were also made by pelleting 1mL of the re-suspended cell culture in a new falcon tube. 
The cell pellet was then re-suspended in 10mL of DMEM with 5% DMSO. 1mL was then 
transferred into 2mL cryovials that were stored at -80⁰C overnight, and then transferred 
to -150⁰C. 
 
RSV Stocks 
 RSV stocks were isolated and propagated within HEp-2 cells previously within 
the lab, and two strains were utilized for this research. The first strain was RSV-Line19-
A2, and the second strain was a modified version that had an RFP-expressing gene, 
RFP-RSV-Line19-A2. The RFP expressing virus was utilized in the experiments. 
 
 RSV Plaque Assay 
HEp-2 cells were seeded at 60% confluency in a 24-well plate, and then the 
plaque assay was initiated when the cells reached 90-100% confluency. Initially, serial 
dilutions of the isolated RSV stock solution were prepared in OptiMEM supplemented 
with 2% FBS. The initial dilution used 40μl of the isolated RSV stock, and the following 
obtained RSV from the previous dilution, as the table below shows. 
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Dilution  1:100 1:1000 1:5000 1:25,000 1: 125,000 
1: 
625,000 
1: 
3,125,000 
RSV:OptiMEM 40μl: 360μl 
40μl: 
360μl 
80μl: 
320μl 
80μl: 
320μl 
80μl: 
320μl 
80μl: 
320μl 
80μl: 
320μl 
 
Table 1. Serial Dilutions of RSV stock for Plaque Assay 
 
 The media that the HEp-2 cells were grown in was removed, and replaced with 
1mL of the supplemented OptiMEM. Then 100μl of each serial dilution was added in 
subsequent order from 1:100 to 1:500,000, and then one well was left un-infected as a 
blank. The above serial dilutions prepare enough RSV to perform two plaque assays 
per 24-well plate. The plate was incubated at 37⁰C for 1.5 hrs, and was mixed every 15 
mins. The media in the plate was then removed from every well and replaced with 1mL 
of 0.8% Methyl Cellulose prepared in DMEM supplemented with 5% FBS and 1% P/S. 
(The day before, 480mg of Methyl Cellulose is autoclaved in a glass jar, along with a 
stirring rod, and then 60mL of the supplemented DMEM is added. The jar was then 
placed on a stirring plate for 2-3 hrs, and then kept at 4⁰C overnight so that the Methyl 
Cellulose is completely dissolved.) The plate was then incubated at 37⁰C for 6 days. On 
the sixth day, the 0.8% Methyl Cellulose media was removed, and the wells are washed 
with 1X PBS. Then the cells were fixed with 10% pre-buffered Formalin solution. 1mL 
was added per well, and then the plate was wrapped in aluminum-foil and placed at 4⁰C 
overnight. The next day, the 10% formalin was removed, and the wells were washed 
with 1X PBS. Then the cells were stained by adding 1mL of 1% Crystal Violet 
(0.01g/mL) to each well, and incubating at room temperature for 10 mins. The Crystal 
Violet was then removed, and the wells were washed with 1X PBS. The plaques were 
then counted, and the titer was quantified. 
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In Vitro Efficiency Experiments for pSH-NS1-P and HR2-D 
For all the following experiments A549 cells were seeded in 6-well plates in 
DMEM supplemented with 10% FBS and 1%P/S. Experiments were initiated when the 
cells reached 80% confluency.   
 
 pSH-NS1-P Anti-RSV Efficiency 
Transfection with the pSH and pSH-NS1-P plasmids was performed using 
Lipofectamine 3000. One solution was prepared using 250μl OptiMEM and 11.25μl 
Lipofectamine 3000 Reagent. A second solution was prepared using 250μl OptiMEM, 
10μl P3000 Reagent, and 5μg of pDNA. The first solution was then added to the second 
solution, and they were mixed by pipetting up and down. The mixture was incubated at 
room temperature for 5 mins. Then 250μl of the mixture was added to each well, and 
the plate was incubated at 37⁰C for 24 hrs. After 24 hrs, the transfection media was 
removed, and replaced with 2mL of supplemented DMEM. Also, specific wells were 
infected with 0.1 MOI (1.2μl/2mL well) of RFP-expressing RSV line19 A2 strain. The 
plate was again incubated for at least 24 hrs at 37⁰C. For some of the following 
experiments 48 and 72 hr time-points were also used. 
 
HR2-D Anti-RSV Efficiency 
A HR2-D solution (1μg/μl) was prepared by adding 0.3mg of HR2-D to 300μl of 
supplemented DMEM, and then vortexed until completely dissolved. The desired wells 
of a 6-well plate were pre-incubated with 5μM (30μl) or 20μM (120μl) of HR2-D. After 
the addition the plate was stirred, and incubated at room temperature for 10 mins. Then 
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the desired wells were infected with 0.1 MOI (1.2μl/2mL well) of RFP-expressing RSV 
line19 A2 strain, and the plate was incubated at 37⁰C for 1 hr. The media was then 
removed, and the wells were washed with 1X PBS. 2mL of supplemented DMEM was 
added to each well, and the desired wells were again infected with the same quantity of 
HR2-D. The plate was incubated at 37⁰C for 24 hrs. 
 
Fluorescent Cellular Imaging 
Imaging was completed using the EVOS fluorescent microscope to visualize the 
transmitted view of the A549 cell monolayer and also the GFP and RFP expression by 
the cells. All three views were captured from the same location within the wells. Each 
image was acquired at 10X magnification at 24h, 48h, or 72h time-points relative to the 
infection, RSV or HR2-D. The final images were analyzed using ImageJ (software) by 
applying a color threshold and normalization to the background fluorescence. The 
resulting intensity acquired represents the fluorescence expressed directly by the cells. 
ImageJ was also utilized to overlay the three images to create a single image containing 
the transmitted view and fluorescent expression for GFP and RFP. 
 
RT-PCR 
The total RNA from the transfected and infected treated A549 cells was isolated 
from cells using the reagent, TRIzol (Life Technologies). Each RNA sample was treated 
with recombinant DNase I (Life Technologies) in order to ensure the sample contained 
pure RNA without the presence of contaminating DNA. Then the concentration of RNA 
was measured using the Nanodrop2000. Based on that concentration, 1 μg of RNA was 
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utilized in the formation of cDNA through reverse transcription facilitated by the Maxima 
First Strand cDNA Synthesis Kit for RT-qPCR (Thermo Fisher Scientific). Real time 
PCR was then performed using the SYBR green master mix (Thermo Fisher Scientific). 
 
Flow Cytometry 
Samples were prepared from A549 cells treated with the plasmid transfection 
and/or infection. After 24h post infection, the cell monolayers from a six well plate were 
detached using 1ml of trypsin per well, and then the cells were pelleted using 
centrifugation for 4min at 1,250rpm. The pellet was re-suspended in 4% formalin for 
fixing and incubated for 10mins. The fixed cells were then pelleted using centrifugation, 
and the new pellet was then re-suspended in 250μl of 1X PBS. The samples were then 
analyzed using the LSRII instrument, and 100,000 events were detected per sample. 
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CHAPTER 3:  
RESULTS AND DISCUSSION 
 
Confirmation of pSH Nucleotide Sequence 
Initially, the Ampicillin resistance selectable marker was confirmed through the 
observation of individual colonies that have grown overnight on LB agar plates 
supplemented with ampicillin (100mg/mL). By observing this growth it was concluded 
that the colonies represented E.coli cells that were transformed with pSH , and were 
able to express the plasmid encoded ampicillin resistance. Also, there was no 
extraneous growth observed on the plate or colonies varying in morphology. Based on 
this observation it was concluded that the provided agar stab was not contaminated, 
and the resulting plasmid isolation were expected to provide pure samples of pSH. The 
antibiotic resistance was then confirmed again when normal growth was observed in the 
liquid LB-Ampicillin culture, which was inoculated with the individual colonies. The 
EGFP expression of pSH was confirmed by visualizing transformed cells via fluorescent 
microscopy.  
Additionally, a restriction digest was performed on the isolated pSH plasmid in 
order to confirm the presence and location of the restriction sites required for cloning 
(Fig. 4-A). The digested DNA products analyzed using AGE were found to produce the 
expected bands based upon the dictation from the plasmid map (Fig. 4-B). A sample of 
non-digested pSH was run as a control, and a thick band was observed at the expected 
27 
 
size. The additional bands seen in the pSH well represent the different confirmations of 
the plasmid that are naturally present in solution, such as supercoiled and nicked 
structures. From this gel, the plasmid maps dictation of pSH was confirmed. 
 
 
 Restriction Enzyme Expected Bands  (bps) 
1 KpnI, EcoRI, XhoI, and PstI 5260, 863, 398, 107 
2 KpnI, EcoRI, and XhoI 5260, 1261, 107 
3 KpnI and EcoRI 6521, 107 
*pSH – control, undigested 6,628 
 
 
Figure 4. Restriction Digest of pSH to confirm sequence. (A) Table of restriction enzymes used in each 
digestion reaction and the expected bands to be seen on the gel image (B) 
 
Cloning of pSH-NS1-P 
The cloning of pSH with the shNS1 and shP dsDNA inserts was confirmed to be 
successful based upon the following results. Multiple digestion and ligation reactions 
were performed, which formed recombinant plasmids with one or both inserts, pSH-
NS1, pSH-P, and pSH-NS1-P. A sample of each ligated plasmid was analyzed using a 
restriction digestion to confirm the success of the reaction and also the plasmids 
integrity. The analysis of the digested fragments was completed using AGE, and 
resulted in the production of bands that matched the expected sizes (Fig 5-A). The 
presence of the insert DNA was seen as the band at 114bp for NS1 and 109bps for P. 
Additionally, the ligated plasmid’s structural integrity was assumed to be maintained 
through the cloning process due to the absence of non-expected bands, and the 
presence of distinct bands matching the expected size. 
1 2 3 pSH 
(A)
 
(B)
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PCR was performed on the pSH-NS1-P plasmid using primers that bound within 
the insert DNA sequences. The forward primer was complementary to the last few 
nucleotides of the sequence upstream from the NS1 insert, and the second half of the 
primer was complementary to the first few nucleotides of the NS1 insert. This primer 
was designed so that binding could only occur if the NS1 insert was successfully 
ligated.   The reverse primer was complementary to a sequence downstream from the P 
insert. This primer was selected because without the presence of the P insert in the 
plasmid the resulting PCR product would be 109bps shorter. However, the resulting 
PCR products matched the expected size of 349bps, and again confirmed the 
successful ligation of the NS1 and P inserts into the pSH backbone (Fig. 5-B). 
 
 
Figure 5. Restriction digest of pSH-NS1-P analyzed via AGE (A). PCR products produced from the pSH-
NS1-P (B). 
 
 
Synthesis of Anti-RSV Nanotherapeutic 
 Overall, the resulting NP from each step of the synthesis procedure was 
characterized, and found to represent the expected physiochemical properties. Each NP 
(A) (B) 
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was characterized based upon the final size, zeta-potential, and visual appearance 
obtained via TEM.  
 The CP NPs from the first step 
were found to have a size of 91.5nm 
(Fig. 6-A). In the TEM images the 
complexes were observed, and 
presented morphological feature 
matching those described in existing 
publications (Fig. 6-D & -E). 
Additionally, the strength of the 
complexation between chitosan and 
the pDNA was analyzed using AGE by 
loading samples of the CP NPs onto a 
1% agarose gel. The different samples 
had varying weight to weight ratios that 
increased in the amount of pDNA that 
was used (left to right, Fig 6-B). After 
an hour at 70hz, no pDNA was seen to 
be released from the CP NPs that had a ratio above 1:1, but in the sample with a ratio 
of 1:0.56 the plasmid was seen to be released. From this data it was concluded that the 
interaction between the chitosan and pDNA was stable with larger amounts of pDNA, 
which is likely due to the saturation of the chitosan NPs with pDNA. The transfection 
capability of these CP NPs was analyzed by observing plasmid-encoded fluorescence 
Figure 6. Analysis of CP (1:1). (A) Size and Zeta 
potential measured with Malvern DLS. (B) 
Encapsulation Efficiency of pDNA within the 
Chitosan Complex. (C) Efficiency of HEK293 
Transfection using CP (4μg/ml DNA). (D) TEM 
500nm scale. (E) TEM 100nm scale 
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from within cells via microscopy. HEK293 cells were transfected with CP NPs bound 
with the RFP-expressing pTom plasmid, and were found to efficiently allow for plasmid 
expression (Fig. 6-C). 
 The CP NPs were then encapsulated 
within theliposome nanocarrier during the 
second synthesis step, and the resulting size 
was 101.6nm (Fig. 7-A). From the resulting 
TEM images, it was visually confirmed that 
the CP NPs were present within the inner 
compartment of the liposomes (Fig. 7-B).  
 The final step of the synthesis was 
performed using the chitosan coating without 
the two antibodies. The chitosan coating 
increased the size to 132.6nm (Fig. 8). The 
chitosan layer was visually confirmed by the 
observation of a dark, thick ring surrounding the structure of the liposome. The 
incorporation of the antibodies will be performed during future work, but is also expected 
to increase the size of the final NP. 
 
 
 
 
Figure 8. Analysis of CP-Liposome with chitosan coating. (A) Size 
measured with Malvern DLS. (B) TEM - 20nm scale.  
Figure 7. Analysis of CP encapsulated within 
DPPC:Chol liposome (2:1). (A) Size measured 
with Malvern DLS. (B)(C) TEM image 50nm & 
20nm scale. (D) TEM images of each component 
of the CP-liposome 
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In vitro Efficiency Experiments 
 pSH-NS1-P 
 The first in vitro experiment performed, as described previously, resulted in cell 
populations that were significantly affected by the anti-RSV effects of pSH-NS1-P. The 
fluorescent microscopy images represented the decrease in the total RFP fluorescence 
expressed from cells infected with the modified Red-RSV-Ln19-A2 strain used during 
infection. The GFP expression was also visualized in order to determine the transfection 
efficiency, and the quantity of cells that are both infected and transfected. Based upon 
these results, pSH-NS1-P was found to express significant anti-RSV properties that 
were maintained at the 72h time point. The other variable measured in these 
experiments regarded the comparison between the anti-RSV activities of pSH-NS1-P 
and the non-ligated pSH (Fig. 9-A). Although pSH was found to present minor anti-RSV 
effects, it can be assumed that this was the result of the lipofectamine3000 agents used 
in the transfection. Additionally, the effect of pSH-NS1-P resulted in significantly less 
RFP expression in comparison to pSH. Based upon these results it can be concluded 
that the observed anti-RSV effect is due to the inhibition imparted by the shRNA’s (Fig. 
9-B).  
RT-PCR was then performed on the total RNA from the A549 cell cultures that 
were analyzed 72h post-infection during the fluorescent experiments. The purpose for 
this experiment was to confirm that the NS1 and P inserts were both contributing to the 
observed anti-RSV effects. Based upon the results, the expression of the NS1 and P 
genes were found to be downregulated in the cells that were infected and transfected. 
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Therefore, it was concluded that pSH-NS1-P is producing active shRNA’s for the 
silencing of both the NS1 and P gene (Fig. 10) 
 
 
 
 
 
 
 
(A) 
(B) 
Fig 9. Intensity of RFP Expression from RSV in Transfected Cells. Trial1 (A) & Trial 2 (B) 
 
Fig 10. RT-PCR of P and NS1 Gene 
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Flow Cytometry was the final analysis performed on the A549 cells from the 
transfection experiment. For this experiment cells were taken from the 24h time point of 
the second trial that included the control pSH. It was found that the transfected and 
infected cells had the lowest number of events representing infected RFP-expressing 
cells. It was found that there was a population of cells expressing both GFP and RFP, 
and also populations expressing GFP or RFP. It was expected that these three 
populations would exist since pSH-NS1-P does not inhibit RSV’s cellular infection, but 
instead inhibits RSV’s replication and propagation from that cell. Therefore, it is 
beneficial to the anti-RSV effects of the plasmid for the transfected cells to become 
infected, or vis versa, so that the RNA interference can take place. Based upon these 
results the wells transfected with 
pSH-NS1-P were found to 
contain the smallest population 
of RFP-expressing infected only 
cells, which supports the trend 
observed in the previous 
experiments (Fig. 11) 
 
 
 HR2-D 
This experiment was performed on a separate culture of A549 cells that were 
treated with HR2-D. This was completed as a “proof-of-concept” experiments since 
there is existing publications that have proven HR2-D efficiency. However, the results of 
this experiment confirmed that the HR2-D stock that was order was effective (Fig 12). It 
Figure 11. Flow cytometry of total percent of RFP 
expressing cells 
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was found that using 5μM of HR2-D exemplified significant anti-RSV effects in 
comparison to the cells that were not treated with HR2-D.  
  
  
 
 
 
 
 
Fig 12. HR2-D Efficiency Assay 
 
In vivo Biodistribution 
A preliminary biodistribution study was performed through the intranasal 
administration of the chitosan coated CP-loaded liposome formulation from section #. 
Cy 5.5 was used to label the chitosan coating, and Cy 7 was used to label the CP NPs. 
For both components the total flux was found to peak in the lungs at 4h post-
administration, and both were observed to produce a signal at the 48h time point (Fig. 
13).  
 
 
 
 
 
 
 
Fig 13. In vivo Biodistribution of Chitosan-coated CP-loaded Liposome 
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CHAPTER 4:  
CONCLUSION 
Overall, this research exemplified the initial phases of the development of a novel 
anti-RSV nanotherapeutic for the dual-inhibition of RSV infection, replication, and 
propagation. Additionally, the results acquired up to this point have supported the 
expectations of the proposed hypothesis, and both aims of the project have been 
satisfied. In regards to Aim 1, the cloning of the recombinant pSH-NS1-P plasmid was 
successfully completed, and the initial in vitro experiments have shown the anti-RSV 
activity of both the NS1 and P inserts in transfected cell populations. In regards to Aim 
2, the synthesis of the nanotherapeutic has been successfully completed, and 
confirmed through TEM imaging. However, the final addition of the two anti-RSV 
antibodies will be completed in future work. Based upon these results the future goals of 
this project will be to analyze the anti-RSV efficiency of the anti-viral mechanisms, pSH-
NS1-P and HR2-D, within the same experiment in order to observe the expected 
synergistic effects. Additionally, future experiments will focus on analyzing the efficiency 
of administering both mechanisms within the proposed nanotherapeutic. In conclusion, 
this research has generated an effective anti-RSV shRNA-expressing plasmid, and a 
non-toxic and biocompatible nanocarrier for the enhanced delivery to the site of RSV 
infection. Once the final formulation has been synthesized and analyzed, the final goal 
would be to produce an affordable intranasal formulation that can confer prolonged and 
enhanced prophylactic effects against RSV. 
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